To summarize the clinicopathological characteristics and survival outcomes of pediatric non-Hodgkin lymphoma (NHL) in Fujian Province. Clinical data of 294 newly diagnosed pediatric NHL patients treated at multiple centers in Fujian Province from January 2011 to December 2023 were collected. The characteristics of different pathological subtypes were summarized, Kaplan-Meier survival analysis were performed and Cox proportional hazards regression model was used for prognostic analysis. A total of 294 pediatric NHL patients were included in this study, with a male-to-female ratio of 3.03∶1 and a median age of 7 years (range, 0.9-14 years). The most common subtype was mature B-cell lymphoma, accounting for 59.2% of cases. The majority of patients were diagnosed at stage III/IV (86.2%), with 32 cases (10.9%) involving central nervous system (CNS) infiltration and 89 cases (30.3%) showing bone marrow involvement. The rate of voluntary abandonment significantly decreased after 2018 (abandonment rates before and after 2018: 6/110 (5.45%) vs. 1/184 (0.54%), P =0.012). Furthermore, excluding cases of voluntary abandonment, the 5-year EFS and OS of newly diagnosed pediatric NHL patients from 2018 to 2023 were still significantly higher than those diagnosed from 2011 to 2017 (EFS: 79.3%±3.7% vs. 70.2%±4.5%, P =0.032; OS: 87.7%±2.6% vs. 70.2%±4.5%, P < 0.001). OS improvements after 2018 were significant in patients with BL and LBL (BL: 89.3%±3.6% vs. 73.5%±7.6%, P =0.033; LBL: 89.3%±5.3% vs. 56.5%±10.3%, P =0.001). However, there were no statistically significant differences in EFS or OS for patients with ALCL or DLBCL (all P >0.05). Multivariate survival analysis identified concurrent hemophagocytic lymphohistiocytosis syndrome was an independent risk factors for both EFS and OS in pediatric NHL patients. Over the past six years, OS and EFS in children with NHL in Fujian Province have improved markedly, with more pronounced gains in BL and LBL. This trend may be related to the combined effects of reduced voluntary treatment abandonment, more standardized diagnostic and therapeutic pathways, treatment optimization, and updated protocols. HLH at initial diagnosis is an independent risk factor for poor prognosis in pediatric NHL, while remission after two chemotherapy cycles suggests a favorable outcome. 福建省儿童非霍奇金淋巴瘤的临床特征及生存分析. 总结福建省儿童非霍奇金淋巴瘤（NHL）的临床病理特征及生存情况。. 收集2011年1月-2023年12月期间福建省多中心诊治的294例初发NHL患儿临床资料，总结不同病理亚型患儿的临床特征，采用Kaplan-Meier进行生存分析，采用Cox比例风险回归模型进行预后分析。. 共纳入294例NHL患儿，男女比例为3.03 ∶1，中位年龄为7（0.9-14）岁，以成熟B细胞淋巴瘤最常见（59.2%）。绝大多数在诊断时处于Ⅲ/Ⅳ期（86.2%），32例（10.9%）合并有中枢神经系统浸润，89例（30.3%）伴有骨髓浸润。总体5年无事件生存（EFS）率和总生存（OS）率分别为74.0%±2.7% 和79.1%±2.5%。2018年后主动放弃率显著降低［2018年前后放弃率分别为6/110（5.45%）、1/184（0.54%）, P =0.012］，而且剔除主动放弃病例后，2018-2023年期间初诊NHL患儿5年EFS、OS仍均显著高于2011-2017年初诊患儿（EFS：79.3%±3.7% 对 70.2%±4.5%，P =0.032；OS：87.7%±2.6% 对 70.2%±4.5%， P < 0.001），其中以伯基特淋巴瘤（BL）和淋巴母细胞淋巴瘤（LBL）最为显著（BL：89.3%±3.6% 对 73.5%±7.6%，P =0.033；LBL：89.3%±5.3% 对 56.5%±10.3%，P =0.001），而ALCL及DLBCL患儿的EFS及OS差异无统计学意义（均P >0.05）。多因素生存分析结果显示，合并噬血细胞综合征是NHL患儿EFS和OS的独立危险因素，化疗2疗程后达到缓解则是EFS和OS预后良好因素。. 近6年来，福建省儿童NHL的OS及EFS明显改善，尤以BL和LBL更为突出。这一趋势可能与主动放弃率下降、诊疗流程规范化、治疗优化以及方案更新等多因素共同作用相关。初诊合并HLH是儿童NHL不良预后的独立危险因素，而2疗程后达到缓解则提示预后良好。.
使用 AI 将内容摘要翻译为中文，便于快速阅读
使用 AI 分析这篇文章的核心发现、关键要点和深度见解
由 DeepSeek AI 提供分析 · 首次使用需配置 API Key
PubMed · 2026-06-01
PubMed · 2026-06-01
PubMed · 2026-06-01
PubMed · 2026-06-01